ArticleAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2026
Lower mortality risk associated with remdesivir plus corticosteroids vs corticosteroids alone for the treatment of patients hospitalized with SARS-CoV-2 infection in the early and later Omicron periods.
Article in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to pose a risk to vulnerable populations. This retrospective study compared the effectiveness of remdesivir plus corticosteroids (CCS) versus CCS alone in patients hospitalized with COVID-19 from December 2021 to December 2024.
methodsData were extracted from a large, geographically-diverse US Premier Healthcare Database for adults hospitalized for COVID-19. Exclusion criteria included pregnancy, incomplete data, transfer from another hospital or hospice care, death/discharge during the baseline period, elective procedure admissions, patients without supplemental oxygen in hospitals that did not report charges for low-flow oxygen, and patients on extracorporeal membrane oxygenation. Propensity score matching was used to balance the distribution of underlying confounders in the two treatment groups. A Cox proportional hazards model was used to assess time to 14- and 28-day inpatient all-cause mortality.
resultsA total of 104,900 patients were initiated on remdesivir plus CCS and 66,016 were initiated on CCS alone in the first 2 days of hospitalization. Unadjusted 14- and 28-day mortality rates were lower for remdesivir-treated patients versus patients who did not receive remdesivir during hospitalization. Remdesivir plus CCS initiation upon admission for COVID-19 (in the total population) was associated with a significantly lower mortality rate (P < 0.0001) (in the overall Omicron period) at both 14 and 28 days, with an adjusted hazard ratio (95% confidence interval) of 0.77 (0.74-0.80) and 0.79 (0.77-0.82), respectively, versus CCS alone. Results were similar for the total population in the early and later Omicron periods.
conclusionRemdesivir plus CCS was associated with a significant reduction in inpatient all-cause mortality relative to CCS alone in patients hospitalized for COVID-19 across 3 years of the Omicron period, illustrating the utility of the most recent real-world evidence to help inform treatment recommendations for inpatient providers treating patients with SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.